Celgene Awaits FDA Nod To Relaunch Vidaza With Survival Labeling
This article was originally published in The Pink Sheet Daily
Executive Summary
Move capitalizes on failure of Eisai’s Dacogen to show a survival benefit in elderly MDS patients.
You may also be interested in...
Celgene’s Revlimid Gains Blockbuster Status; Vidaza Poised To Gobble MDS Market Share
NICE posts positive recommendation for Vidaza payment in England, Wales.
Celgene’s Revlimid Gains Blockbuster Status; Vidaza Poised To Gobble MDS Market Share
NICE posts positive recommendation for Vidaza payment in England, Wales.
Eisai To Try New Dosing sNDA For Dacogen
Celgene’s Vidaza could take over MDS market after Dacogen’s Phase III failure, analysts say.